{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T02:25:01Z","timestamp":1784773501664,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["OCENW.KLEIN.268"],"award-info":[{"award-number":["OCENW.KLEIN.268"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020407","name":"European Research Area Network on Cardiovascular Diseases","doi-asserted-by":"publisher","award":["ERA-CVD 2019T108"],"award-info":[{"award-number":["ERA-CVD 2019T108"]}],"id":[{"id":"10.13039\/501100020407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.imlet.2025.107092","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T02:26:46Z","timestamp":1758940006000},"page":"107092","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Fatty acid binding protein 2 (FATP2\/SLC27A2) blockade with Lipofermata elicits dual effects on inflammatory responses in human monocytes and macrophages"],"prefix":"10.1016","volume":"277","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2058-5614","authenticated-orcid":false,"given":"Nico","family":"Hahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serhii","family":"Chornyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan","family":"Heister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helga E.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Giera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari\u00ebtte R.","family":"Boon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gijs","family":"Kooij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7852-2891","authenticated-orcid":false,"given":"Jan","family":"Van den Bossche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.imlet.2025.107092_bib0001","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1038\/s41591-019-0675-0","article-title":"Chronic inflammation in the etiology of disease across the life span","volume":"25","author":"Furman","year":"2019","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.imlet.2025.107092_bib0002","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/s41422-020-0291-z","article-title":"Targeting immunometabolism as an anti-inflammatory strategy","volume":"30","author":"Palsson-McDermott","year":"2020","journal-title":"Cell Res"},{"issue":"6","key":"10.1016\/j.imlet.2025.107092_bib0003","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.it.2017.03.001","article-title":"Macrophage immunometabolism: where are we (Going)?","volume":"38","author":"Van den Bossche","year":"2017","journal-title":"Trend Immunol"},{"issue":"9","key":"10.1016\/j.imlet.2025.107092_bib0004","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nri.2016.70","article-title":"Rathmell J. A guide to immunometabolism for immunologists","volume":"16","author":"O'Neill","year":"2016","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.imlet.2025.107092_bib0005","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cmet.2019.11.014","article-title":"The untapped opportunity and challenge of immunometabolism: a new paradigm for drug discovery","volume":"31","author":"Mazumdar","year":"2020","journal-title":"Cell Metab"},{"issue":"8","key":"10.1016\/j.imlet.2025.107092_bib0006","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/bph.14587","article-title":"Lipid mediators in immune regulation and resolution","volume":"176","author":"Gilroy","year":"2019","journal-title":"Br J Pharmacol"},{"issue":"5548","key":"10.1016\/j.imlet.2025.107092_bib0007","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1126\/science.294.5548.1871","article-title":"Prostaglandins and leukotrienes: advances in eicosanoid biology","volume":"294","author":"Funk","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.imlet.2025.107092_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114759","article-title":"Untangling the web of 5-lipoxygenase-derived products from a molecular and structural perspective: the battle between pro- and anti-inflammatory lipid mediators","volume":"193","author":"Gilbert","year":"2021","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"10.1016\/j.imlet.2025.107092_bib0009","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s00296-011-2263-6","article-title":"A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity","volume":"32","author":"Conaghan","year":"2012","journal-title":"Rheumatol Int"},{"issue":"35","key":"10.1016\/j.imlet.2025.107092_bib0010","doi-asserted-by":"crossref","first-page":"30670","DOI":"10.1074\/jbc.M111.226316","article-title":"Human fatty acid transport protein 2a\/very long chain acyl-CoA synthetase 1 (FATP2a\/Acsvl1) has a preference in mediating the channeling of exogenous n-3 fatty acids into phosphatidylinositol","volume":"286","author":"Melton","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.imlet.2025.107092_bib0011","article-title":"Peroxisomal metabolite and cofactor transport in humans","volume":"8","author":"Chornyi","year":"2020","journal-title":"Front Cell Dev Biol."},{"key":"10.1016\/j.imlet.2025.107092_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105228","article-title":"FATP2-targeted therapies - A role beyond fatty liver disease","volume":"161","author":"Qiu","year":"2020","journal-title":"Pharmacol Res"},{"issue":"7754","key":"10.1016\/j.imlet.2025.107092_bib0013","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41586-019-1118-2","article-title":"Fatty acid transport protein 2 reprograms neutrophils in cancer","volume":"569","author":"Veglia","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.imlet.2025.107092_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2021.104286","article-title":"Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy","volume":"362","author":"Adeshakin","year":"2021","journal-title":"Cell Immunol"},{"issue":"6 Suppl","key":"10.1016\/j.imlet.2025.107092_bib0015","article-title":"n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases","volume":"83","author":"Calder","year":"2006","journal-title":"Am J Clin Nutr"},{"issue":"2","key":"10.1016\/j.imlet.2025.107092_bib0016","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1365-2249.1995.tb05549.x","article-title":"Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism","volume":"99","author":"Danis","year":"1995","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.1016\/j.imlet.2025.107092_bib0017","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2567.2011.03475.x","article-title":"The toll-like receptor 1\/2 agonists Pam(3) CSK(4) and human beta-defensin-3 differentially induce interleukin-10 and nuclear factor-kappaB signalling patterns in human monocytes","volume":"134","author":"Funderburg","year":"2011","journal-title":"Immunology"},{"key":"10.1016\/j.imlet.2025.107092_bib0018","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.3389\/fimmu.2019.01462","article-title":"The metabolic signature of macrophage responses","volume":"10","author":"Viola","year":"2019","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.imlet.2025.107092_bib0019","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.celrep.2016.09.008","article-title":"Mitochondrial dysfunction prevents repolarization of inflammatory macrophages","volume":"17","author":"Van den Bossche","year":"2016","journal-title":"Cell Rep"},{"issue":"6","key":"10.1016\/j.imlet.2025.107092_bib0020","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.it.2017.03.001","article-title":"Macrophage immunometabolism: where are we (Going)?","volume":"38","author":"Van den Bossche","year":"2017","journal-title":"Trend Immunol"},{"key":"10.1016\/j.imlet.2025.107092_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.734229","article-title":"Reactive oxygen species in macrophages: sources and targets","volume":"12","author":"Canton","year":"2021","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.imlet.2025.107092_bib0022","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1182\/blood-2008-03-146720","article-title":"Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages","volume":"113","author":"Netea","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.imlet.2025.107092_bib0023","article-title":"Van den Bossche J. An integrated toolbox to profile macrophage immunometabolism","volume":"2","author":"Verberk","year":"2022","journal-title":"Cell Rep Methods"},{"issue":"1","key":"10.1016\/j.imlet.2025.107092_bib0024","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.bcp.2015.09.004","article-title":"Chemical inhibition of fatty acid absorption and cellular uptake limits lipotoxic cell death","volume":"98","author":"Ahowesso","year":"2015","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"10.1016\/j.imlet.2025.107092_bib0025","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.bcp.2009.11.008","article-title":"Identification and characterization of small compound inhibitors of human FATP2","volume":"79","author":"Sandoval","year":"2010","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.imlet.2025.107092_bib0026","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s00213-005-0272-4","article-title":"Valproic acid selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by brain microsomal long-chain fatty acyl-CoA synthetases: relevance to bipolar disorder","volume":"184","author":"Bazinet","year":"2006","journal-title":"Psychopharmacol (Berl)"},{"issue":"8","key":"10.1016\/j.imlet.2025.107092_bib0027","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.3324\/haematol.2019.219519","article-title":"Specialized pro-resolving lipid mediators are differentially altered in peripheral blood of patients with multiple sclerosis and attenuate monocyte and blood-brain barrier dysfunction","volume":"105","author":"Kooij","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.imlet.2025.107092_bib0028","doi-asserted-by":"crossref","first-page":"7559","DOI":"10.1038\/s41598-024-58143-2","article-title":"The cyclooxygenase-2 upregulation mediates production of PGE2 autacoid to positively regulate interleukin-6 secretion in chronic rhinosinusitis with nasal polyps and polyp-derived fibroblasts","volume":"14","author":"Shieh","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.imlet.2025.107092_bib0029","doi-asserted-by":"crossref","first-page":"681","DOI":"10.4049\/jimmunol.177.1.681","article-title":"Peptidoglycan-induced IL-6 production in RAW 264.7 macrophages is mediated by cyclooxygenase-2, PGE2\/PGE4 receptors, protein kinase A, I kappa B kinase, and NF-kappa B","volume":"177","author":"Chen","year":"2006","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.imlet.2025.107092_bib0030","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41420-024-01802-0","article-title":"Pyroptotic cell death: an emerging therapeutic opportunity for radiotherapy","volume":"10","author":"Li","year":"2024","journal-title":"Cell Death Discov"},{"issue":"12","key":"10.1016\/j.imlet.2025.107092_bib0031","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.tibs.2016.09.002","article-title":"Mechanism and regulation of NLRP3 inflammasome activation","volume":"41","author":"He","year":"2016","journal-title":"Trends Biochem Sci"}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247825001257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247825001257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T16:51:49Z","timestamp":1781023909000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247825001257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":31,"alternative-id":["S0165247825001257"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2025.107092","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fatty acid binding protein 2 (FATP2\/SLC27A2) blockade with Lipofermata elicits dual effects on inflammatory responses in human monocytes and macrophages","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2025.107092","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Federation of Immunological Societies.","name":"copyright","label":"Copyright"}],"article-number":"107092"}}